Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes

NCT02057172 · Completed

Last updated 2026-05-28

This clinical trial is testing whether a weekly injection of LAPS-Exendin lowers blood sugar levels in adults with type 2 diabetes compared to a placebo over 12 weeks.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 254 people

Who can join Ages 18–74 · all sexes

Timeline Started 2014-01 · est. completion 2014-12

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT02057172 ↗

Description as written by the study sponsor.

The purpose of this study is to determine the optimal dose or doses of HM11260C, when administered once a week under the skin, to improve the control of blood sugar levels in patients with early-stage type 2 diabetes mellitus (T2DM).

Treatments tested

HM11260C also known as LAPS-Exendin-4 Drug

HM11260C is a novel long-acting form of CA Exendin-4 (an Exendin-4 analogue)
liraglutide also known as Victoza Drug

Liraglutide is a GLP-1 agonist.
Placebo Drug

Placebo

Main thing measured	Change in baseline in glycosylated haemoglobin (HbA1c) at 12 weeks
Sponsor	Hanmi Pharmaceutical Company Limited
Conditions studied	Type 2 Diabetes
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02057172 ↗